Research programme: complement C1 inhibitor protein - iBio

Drug Profile

Research programme: complement C1 inhibitor protein - iBio

Latest Information Update: 28 Mar 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator iBio Inc
  • Class Biological proteins; Proteins
  • Mechanism of Action Complement C1s inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • Available For Licensing Yes - Hereditary angioedema

Highest Development Phases

  • Preclinical Hereditary angioedema

Most Recent Events

  • 26 Mar 2013 iBio selects a recombinant C1 esterase inhibitor product candidate for clinical development for Hereditary agioedema in USA
  • 26 Mar 2013 Recombinant C1 esterase inhibitor protein is available for partnering for clinical development
  • 18 Nov 2011 Preclinical trials in Hereditary angioedema in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top